Analyst Reco. Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Real-time Estimate Cboe BZX Other stock markets 10:09:00 2024-05-21 am EDT			5-day change	1st Jan Change
3.505 ^USD	-2.37%		-11.99%	-28.88%

May. 07	Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M	MT
May. 07	Adaptive Biotechnologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating	Feb. 15	MT
Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating	23-10-24	MT
BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating	23-10-20	MT
Morgan Stanley Trims Adaptive Biotechnologies' Price Target to $15 From $16, Maintains Equalweight Rating	23-02-16	MT
Scotiabank Initiates Adaptive Biotechnologies at Sector Outperform Rating With $15 Price Target	23-01-05	MT
Scotiabank Initiates Adaptive Biotechnologies at Sector Outperform With $15 Price Target	23-01-05	MT
Piper Sandler Upgrades Adaptive Biotechnologies to Overweight From Neutral, Adjusts Price Target to $14 From $7.50	22-12-21	MT
Morgan Stanley Adjusts Price Target on Adaptive Biotechnologies to $16 From $17, Maintains Equalweight Rating	22-11-07	MT
Piper Sandler Adjusts Price Target on Adaptive Biotechnologies to $7.50 From $12, Maintains Neutral Rating	22-10-26	MT
Credit Suisse Initiates Adaptive Biotechnologies at Underperform with $8 Price Target	22-08-25	MT
Credit Suisse Initiates Coverage of 20 Companies in Life Science Tools, Services, Diagnostics Sectors; Outperform-Rated Bio-Rad, IQVIA, Bipo-Techne, Natera Named Top Picks	22-08-25	MT
Piper Sandler Increases Price Target on Adaptive Biotechnologies to $12 From $7.50, Reiterates Neutral Rating	22-08-18	MT
BTIG Adjusts Price Target for Adaptive Biotechnologies to $17 From $25, Maintains Buy Rating	22-08-04	MT
Piper Sandler Starts Adaptive Biotechnologies at Neutral With $7.50 Price Target	22-06-03	MT
Goldman Sachs Adjusts Adaptive Biotechnologies' Price Target to $10 from $14, Keeps Neutral Rating	22-05-24	MT
Goldman Sachs Adjusts Adaptive Biotechnologies' Price Target to $21 from $54, Maintains Neutral Rating	22-02-16	MT
JPMorgan Adjusts Adaptive Biotechnologies' Price Target to $50 from $75, Maintains Overweight Rating	22-02-16	MT
BTIG Adjusts Adaptive Biotechnologies' Price Target to $30 from $35, Maintains Buy Rating	22-02-16	MT
Morgan Stanley Adjusts Adaptive Biotechnologies Price Target to $27 From $46, Maintains Equalweight Rating	22-02-15	MT
BTIG Adjusts Adaptive Biotechnologies' Price Target to $45 From $55; Buy Rating Kept	22-01-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Analyst Reco.

Filters